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Abstract
NMDA receptors (NMDARs) are involved in excitatory synaptic transmission and plasticity
associated with a variety of brain functions, from memory formation to chronic pain. Subunit-
selective antagonists for NMDARs provide powerful tools to dissect NMDAR functions in neuronal
activities. Recently developed antagonist for NR2A-containing receptors, NVP-AAM007, triggered
debates on its selectivity and involvement of the NMDAR subunits in bi-directional synaptic
plasticity. Here, we re-examined the pharmacological properties of NMDARs in the anterior
cingulate cortex (ACC) using NVP-AAM007 as well as ifenprodil, a selective antagonist for NR2B-
containing NMDARs. By alternating sequence of drug application and examining different
concentrations of NVP-AAM007, we found that the presence of NVP-AAM007 did not significantly
affect the effect of ifenprodil on NMDAR-mediated EPSCs. These results suggest that NVP-
AAM007 shows great preference for NR2A subunit and could be used as a selective antagonist for
NR2A-containing NMDARs in the ACC.
Background
NMDA receptors (NMDARs) have pivotal roles in excita-
tory synaptic transmission and plasticity, and in various
brain processes from memory formation to chronic pain
[1,2]. NMDARs are tetrameric complexes, which contain
two NR1 and two NR2 subunits (NR2A-D). The type of
NR2 subunits determines not only gating properties but
also signaling pathways of NMDARs [3,4]. Therefore, dif-
ferent subunit compositions confer NMDARs distinct
roles in the regulation of neuronal functions. In consist-
ence with this notion, NMDARs could undergo subunit-
specific regulations under physiological or pathological
conditions. For example, NR2A subunit gradually replaces
NR2B in most brain areas during postnatal development
[5], while NR2B but not NR2A is up-regulated in the ante-
rior cingulate cortex (ACC) after peripheral inflammation
[6].
Considering the distinct roles of NMDARs, dissection of
their subtype-selective functions will promote our under-
standing of molecular mechanisms underlying physiolog-
ical and pathological processes, such as memory and pain.
Although pharmacological tools are powerful, subtype-
selective antagonists for NMDARs are not well developed
[7]. Most selective antagonists are ifenprodil and its deriv-
atives (e.g. Ro25-6981), which are more than 200-fold
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preference for NR1/NR2B than for NR1/NR2A [8,9]. A rel-
atively selective NR1/NR2A antagonist, NVP-AAM077
(NVP) was developed recently and found to have more
than 100-fold preferential blockade of NR1/NR2A vs
NR1/NR2B [10]. Using these antagonists, recent studies
have shown that NR2A-containg NMDARs are required
for LTP, whereas NR2B NMDARs are required for LTD
[11,12]. However, the concept of subtype-dependent LTP
and LTD was questioned by other studies that reported
the lack of NMDA subtype receptor selectivity for bi-direc-
tional synaptic plasticity [13-18]. Moreover, some of these
studies also argued that NVP is not sufficient to discrimi-
nate between NR2A- and NR2B-containing NMDARs,
with less than 10-fold selectivity [19,20].
NR2A and NR2B are highly expressed in the ACC, a fore-
brain area involved in emotion, memory and pain
[21,22]. Our recent results indicate that both NR2A and
NR2B are required for the induction of cingulate LTP and
LTD [17,18]. Since previous debates of antagonist selectiv-
ity are based on results mostly obtained from hippocam-
pal neurons and transfected cells, we wanted to re-
examine the pharmacological properties of NMDARs with
NVP and ifenprodil in the ACC. By testing antagonist
effects with different application sequences and concen-
trations, we found that NVP at concentration of 0.4 μM
and 0.1 μM is likely to be relatively selective for NR2A-
containing NMDARs in ACC neurons.
Materials and methods
All adult C57BL/6 mice were purchased from Charles
River and were maintained on a 12 h light/dark cycle with
food and water provided ad libitum. The Animal Studies
Committee at the University of Toronto approved all
experimental protocols. Coronal brain slices (300 μm)
containing the ACC from six- to eight-week-old C57BL/6
male mice were prepared using standard methods [23].
Slices were transferred to a submerged recovery chamber
with oxygenated (95 % O2 and 5 % CO2) artificial cere-
brospinal fluid (ACSF) containing (in mM: 124 NaCl, 2.5
KCl, 2 CaCl2, 2 MgSO4, 25 NaHCO3, 1 NaH2PO4, 10 glu-
cose) at room temperature for at least 1 h.
Experiments were performed in a recording chamber on
the stage of an Olympus BX51WI microscope (Tokyo,
Japan) with infrared DIC optics for visualization of
whole-cell patch clamp recording. Excitatory postsynaptic
currents (EPSCs) were recorded from pyramidal neurons
in layer II/III of the ACC with an Axon 200B amplifier
(Molecular devices, CA) and the stimulations were deliv-
ered by a bipolar tungsten stimulating electrode placed in
layer V. The recording pipettes (3–5 MΩ) were filled with
the solution containing (mM): 145 CsMeSO3, 5 NaCl, 1
MgCl2, 0.2 EGTA, 10 HEPES, 2 Mg-ATP, 10 phosphocrea-
tine, 0.1 Na3-GTP, 5 QX-314 (adjusted to pH 7.2 with
CsOH). NMDA receptor-mediated EPSCs (NMDA EPSCs)
were pharmacologically isolated in ACSF containing
CNQX (20 μM), and picrotoxin (100 μM). Neurons were
voltage clamped at -30 mV and NMDA EPSCs were
evoked at 0.05 Hz. To study NVP- or ifenprodil-sensitive
component in total NMDA EPSCs, NVP or ifenprodil was
bath-applied for 10 min after obtaining stable baseline for
5 min. The NVP- or ifenprodil-sensitive component was
calculated as the reduction of current in the correspond-
ing drugs at the last one minute. NMDA EPSCs were fitted
with single exponential function and decay time constant
reflects the time decaying to 37% of NMDA EPSCs. Access
resistance was 15–30 MΩ and was monitored throughout
the experiment. All antagonists were applied through the
perfusion solution. Data were discarded if access resist-
ance changed more than 15% during an experiment.
Results were analyzed by t-test to identify significant dif-
ferences. All data are expressed as mean S.E.M. In all cases,
P < 0.05 was considered statistically significant.
Results and discussion
Conventional whole-cell patch clamp recordings were
performed in visually identified pyramidal neurons in
layer II/III of ACC slices. NMDA EPSCs were isolated by
adding CNQX (20 μM), an AMPA/KA receptor antagonist,
and picrotoxin (100 μM), a GABAA receptor antagonist.
Since ifenprodil is well accepted for its selectivity on NR2B
NMDARs, whereas NVP on NR2A is a debate, we therefore
employed the occlusion strategy to test NR2B component
with or without pretreatment with NVP. If NVP is non-
selective, that is, inhibiting NR2B, we then expected that
the ifenprodil-sensitive component will be significantly
smaller in the presence of NVP. To test this idea, we first
applied NVP (0.4 μM) for 10 minutes and then applied
ifenprodil (3 μM) for another 10 minutes (Figure 1A and
1B). We calculated the percentage of ifenprodil and NVP
inhibition on NMDA EPSCs. The application of NVP
decreased 70.0 ± 4.7 % (n = 9) while the following appli-
cation of ifenprodil decreased 15.7 ± 2.7 % (n = 9) of total
NMDA EPSCs (Figure 1C). This result is similar to our pre-
vious reports using NVP and Ro25-6981 [6,18].
We also examined the decay time constant of ifenprodil-
sensitive and NVP-sensitive NMDA EPSCs (Figure 1C).
Consistent with our previous reports [6,18], ifenprodil-
sensitive component showed typical slower kinetics (τ =
122.7 ± 8.9 ms) compared with NVP-sensitive NMDA
EPSCs (τ = 100.0 ± 10.5 ms, P < 0.05, paired t-test), show-
ing they are preferentially mediated by NR2B- and NR2A
containing NMDARs, respectively.
Next, we alternated the sequence of drug applications,
that is, we first applied ifenprodil and then applied NVP
(Figure 2A and 2B). The application procedure revealed
that ifenprodil (3 μM) reduced 27.6 ± 7.9 % (n = 8) ofMolecular Pain 2007, 3:11 http://www.molecularpain.com/content/3/1/11
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total NMDA EPSCs. The following perfusion of NVP (0.4
μM) further decrease 57.8 ± 8.3 % (n = 8) of total NMDA
EPSCs (Figure 2C). We compared the percentage of ifen-
prodil-sensitive component between Figure 1C and Figure
2C, statistical results found no significant difference
between two groups using different drug application
sequences (P = 0.21, unpaired t-test). Similarly, we did
not found the significant difference of NVP-sensitive com-
ponent between two groups (P = 0.16, unpaired t-test).
We observed that NMDA EPSCs in different cells have var-
ious responses to ifenprodil and NVP. For example, in 17
cells tested, there are two cells showed around 50 %
reduction when applied ifenprodil, whereas another 3
cells show less than 10 % of ifenprodil-sensitive compo-
nent. To exclude the possibility that the insignificance is
due to the variations among cells, we re-calculated the
data by including the cells showing 10–50% ifenprodil-
sensitive component in total NMDA EPSCs. No difference
was found for ifenprodil-sensitive responses between the
group treated with NVP followed by ifenprodil (18.6 ± 2.4
%, n = 7) and the group treated with ifenprodil followed
by NVP (25.8 ± 2.2 %, n = 5, P = 0.08). Likewise, there is
no difference in NVP-sensitive component between the
two groups (65.4 ± 4.3 % vs 60.2 ± 3.9 %, P = 0.45). Taken
together, these results suggest that NVP does not signifi-
cantly affect NR2B component and could be used as a
selective antagonist for NR2A-containing NMDARs in the
ACC.
To confirm the idea, we further tested the lower concen-
tration (0.1 μM) of NVP (Figure 3). We found that the
application of NVP (0.1 μM) decreased 53.2 ± 3.2 % (n =
7) while the following application of ifenprodil (3 μM)
decreased 19.6 ± 1.3 % (n = 7) of total NMDA EPSCs (Fig-
ure 3A and 3C). Under these conditions, ifenprodil-sensi-
tive component showed slower kinetics (τ = 123.5 ± 7.9
ms) compared with NVP-sensitive NMDA EPSCs (τ = 95.3
± 8.2 ms, P < 0.05, paired t-test). When we alternated the
sequence of drug application, the perfusion of ifenprodil
decreased 24.9 ± 4.4 % (n = 5) and following NVP
decreased 43.3 ± 5.3 % (n = 5) of total NMDA EPSCs (Fig-
ure 3B and 3C). No difference was found for percentage of
ifenprodil-sensitive component between two groups (P =
0.27, unpaired t-test, Figure 3C). Similarly, no difference
was found for percentage of NVP-sensitive component
between two groups (P = 0.16, unpaired t-test, Figure 3C).
Therefore, the lower concentration (0.1 μM) of NVP did
not significantly affect NR2B-containing NMDARs in the
ACC neurons.
Since alternating sequences of drug application did not
significantly affect their effects on NMDA EPSCs, the data
were then pooled together (Figure 4). We found that
NR2A component obtained by application of 0.4 μM NVP
Effects of NVP followed by ifenprodil on NMDA EPSCs in  ACC neurons Figure 1
Effects of NVP followed by ifenprodil on NMDA 
EPSCs in ACC neurons. A, A single example showing the 
effect of sequential application of NVP (0.4 μM) and ifen-
prodil (3 μM) on NMDA EPSCs. The insets show average of 
3 EPSCs at the time point (1, 2 and 3) indicated in the graph. 
B, Pooled data showing NVP largely decreased NMDA 
EPSCs and ifenprodil abolished the residual EPSCs. C, Bar 
graphs showing the average percentage (left) and decay time 
constant (right) of NVP- and ifenprodil-sensitive components 
after sequential application of NVP and ifenprodil.Molecular Pain 2007, 3:11 http://www.molecularpain.com/content/3/1/11
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and 0.1 μM NVP is 64.3 ± 4.7 % (n = 17) and 49.0 ± 3.4
% (n = 12), which are significantly different from each
other (P < 0.05, unpaired t-test). In contrast, there is no
difference of NR2B component by 3 μM ifenprodil in two
groups, which was 21.3 ± 4.2 % (n = 17) and 21.8 ± 2.3 %
(n = 12) (P = 0.93, unpaired t-test), respectively. There-
fore, high concentration of NVP (0.4 μM) did not affect
NR2B component, whereas lower concentration of NVP
(0.1 μM) is not effective enough in inhibiting NR2A-con-
taining NMDA receptors in ACC neurons.
Effects of the lower concentration of NVP and ifenprodil on NMDA EPSCs in ACC neurons Figure 3
Effects of the lower concentration of NVP and ifenprodil on NMDA EPSCs in ACC neurons. A, Pooled data 
showing the effect of sequential applications of NVP (0.1 μM) and ifenprodil (3 μM) and on NMDA EPSCs. B, Pooled data 
showing the effect of sequential application of ifenprodil (3 μM) and NVP (0.1 μM) on NMDA EPSCs. C, Bar graphs showing 
the average percentage of NVP- and ifenprodil-sensitive component after sequential application of NVP (0.1 μM) + ifenprodil 
or ifenprodil + NVP.
Effects of ifenprodil followed by NVP on NMDA EPSCs in ACC neurons Figure 2
Effects of ifenprodil followed by NVP on NMDA EPSCs in ACC neurons. A and B, A representative example (A) 
and pooled data (B) showing the effect of sequential applications of ifenprodil (3 μM) and NVP (0.4 μM) on NMDA EPSCs. C, 
The bar graph showing the average percentage of NVP- and ifenprodil-sensitive components after sequential application ifen-
prodil and NVP.Molecular Pain 2007, 3:11 http://www.molecularpain.com/content/3/1/11
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In the presence study, we used pharmacological tools to
isolate postsynaptic currents mediated by NR2A- and
NR2B-containing NMDARs, respectively. By alternating
sequence of drug applications, we found that the presence
of NVP did not significantly affect the effect of ifenprodil
on NMDA EPSCs, suggesting that NVP is relatively selec-
tive for NR2A-containing NMDARs. There are several con-
cerns related to our conclusions. First, it has been reported
the regional difference of NMDARs in the ACC and hip-
pocampus, such as NR2A/NR2B ratio, phosphorylated
NR2A and NR2B [18] as well as regulations under chronic
pain conditions [6]. Therefore, the current results may not
fully applied to other brain areas including hippocampus.
Indeed, it has been reported that 0.4 μM NVP could block
one third of Ro-6981-sensitive NMDA EPSCs in cultured
hippocampal neurons [24]. In the current study, due to
the difficulty in washing out the drugs in slices, we cannot
use the same way to calculate the possible effect of NVP on
ifenprodil-sensitive component; Second, although it is
difficult to reconcile the discrepancy for NVP and ifen-
prodil selectivity in different systems, the various reports
may be due to complex subunit composition, spatial dis-
tributions of NMDARs, and their related scaffolding mol-
ecules [4,7]. For instance, triheteromeric NMDA receptor,
NR1/NR2A/NR2B, has been found in native tissues, par-
ticularly in the cortex [5,25]. Moreover, it was shown that
NR1/NR2A/NR2B is also highly sensitive to ifenprodil
[26]. Alternatively, it has been proposed that there are
potential interactions for NR2A and NR2B [27], which
may also account for the variability. Therefore, first per-
fusion of NVP or ifenprodil might affect the following
effect of ifenprodil or NVP. Third, due to the limitation of
conventional whole-cell recording, we observed the run-
down of NMDA EPSCs during 25 minutes in some of neu-
rons (3 out 7 neurons). Although the pooled data showed
no significance in the reduction of NMDA EPSCs (12.9 ±
6.6 % of control, n = 7, P = 0.13, paired t-test), the result
may confound the contribution of NVP- and ifenprodil-
Pooled data of NR2B and NR2A component in ACC neurons Figure 4
Pooled data of NR2B and NR2A component in ACC neurons. The percentages of NVP- and ifenprodil-sensitive com-
ponents in each neuron were plotted in two groups: 0.4 μM NVP + 3 μM ifenprodil (filled circle) and 0.1 μM NVP + 3 μM ifen-
prodil (open triangle). Although no difference in ifenprodil-sensitive component, there is significant shift in NVP-sensitive 
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sensitive component. Last, we were aware the variability
of percentage of NR2B component in ACC neurons. In all
tested 29 neurons, we found 4 neurons have much
smaller ifenprodil-sensitive current (<10% of total cur-
rents, Figure 4). Future experiments (e.g. single cell RT-
PCR) are needed to test the possibility that whether these
neurons express less NR2B subunits.
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